Combination drug therapy for chronic lymphocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs—nemtabrutinib, venetoclax, and obinutuzumab—for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this combination is safe and effective in treating the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of CLL or SLL.
- You must need treatment for your CLL/SLL according to standard guidelines.
- Your overall health should be reasonably good (able to care for yourself, up and about).
- Your blood counts, liver, and kidney function must be within certain limits, unless low counts are due to the leukemia.
- You must be able to swallow pills.
- If you are of childbearing potential, you must agree to use effective contraception or be abstinent during the study and for 6 months after.
- You must not have had prior treatment with a BTK inhibitor (like ibrutinib) or a BCL2 inhibitor (like venetoclax).
- You must not have active hepatitis B or C, or uncontrolled HIV.
- You must not have had major surgery within 4 weeks or have ongoing surgical complications.
- You must not have a history of another cancer that is not considered cured (unless it's a non-melanoma skin cancer or certain early-stage cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests two oral medications, nemtabrutinib and venetoclax, given together to people with untreated CLL or SLL. The goal is to see if this combination effectively kills cancer cells and helps you stay in remission with manageable side effects.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
This trial is testing a combination of three targeted drugs (tafasitamab, acalabrutinib, and venetoclax) for people with CLL or SLL who have not yet received treatment. The goal is to see if this combination is effective and manageable.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and bendamustine) as a first treatment for chronic lymphocytic leukemia (CLL). The goal is to see if this combination is safe and effective for people who have not yet received any treatment for CLL.
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.